Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease

Exercise Immunology Review

Volumn 11, Issue , 2005, Pages 97-107

  König, Daniel ^a   Deibert, P ^a   Winkler, K ^a   Berg, A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Coronary heart disease; Inflammation; LDL cholesterol; Lipid lowering drugs; Physical activity

Indexed keywords

BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; EXERCISE; HUMAN; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED;

AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY DISEASE; EXERCISE; HUMANS; INFLAMMATION; MIDDLE AGED;

EID: 33646380376     PISSN: 10775552     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497; 2001.
2. Abuja, P. M. Bimonthly update. Atherosclerosis: cell biology and lipoproteins. Curr. Opin. Lipidol. 11:441-443; 2000.
3. Anonymous Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389; 1994.
4. Aronson, D. Inflammatory markers: linking unstable plaques to coronary event, an interventional perspective. /Int. J. Cardiovasc. Intervent./ 6:110-118; 2004.
5. Benzaquen, L. R.; Yu, H.; Rifai, N. High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. Crit Rev. Clin. Lab Sci. 39:459-497; 2002.
6. Berg, A.; Halle, M.; Franz, I.; Keul, J. Physical activity and lipoprotein metabolism: Epidemiological evidence and clinical trials. Eur. J. Med. Res. 2:259-264; 1997.
7. Cesari, M.; Penninx, B. W.; Newman, A. B.; Kritchevsky, S. B.; Nicklas, B. J.; Sutton-Tyrrell, K.; Rubin, S. M.; Ding, J.; Simonsick, E. M.; Harris, T. B.; Pahor, M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108:2317-2322; 2003.
8. Church, T. S.; Barlow, C. E.; Earnest, C. P.; Kampert, J. B.; Priest, E. L.; Blair, S. N. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler. Thromb. Vasc. Biol. 22:1869-1876; 2002.
9. Cushman, M.; Arnold, A. M.; Psaty, B. M.; Manolio, T. A.; Kuller, L. H.; Burke, G. L.; Polak, J. F.; Tracy, R. P. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112:25-31; 2005.
10. Danesh, J.; Lewington, S.; Thompson, S. G. et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799-1809; 2005.
11. Eriksson, M.; Egberg, N.; Wamala, S.; Orth-Gomer, K.; Mittleman, M. A.; Schenck-Gustafsson, K. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler. Thromb. Vasc. Biol. 19:67-72; 1999.
12. Ford, E. S. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology. 13:561-568; 2002.
13. Grundy, S. M. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am. J. Cardiol. 75:45B; 1995.
14. Grundy, S. M. Role of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin. Chem. 41:139-146; 1995.
15. Halle, M.; Berg, A.; König, D.; Keul, J.; Baumstark, M. W. Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men. Metabolism 46:186-191; 1997.
16. Hamano, M.; Saito, M.; Eto, M.; Nishimatsu, S.; Suda, H.; Matsuda, M.; Matsuki, M.; Yamamoto, S.; Kaku, K. Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease. Ann. Clin. Biochem. 41:125-129; 2004.
17. Hambrecht, R.; Niebauer, J.; Marburger, C.; Grunze, M.; Kälberer, B.; Hauer, K.; Schlierf, G.; Kübler, W.; Schuler, G. Various intensities of leisure time physical activity in patients with coronary artery disease: effects of cardiorespirative fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol 22:468-477; 1993.
18. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352:1685-1695; 2005.
19. Haskell, W. L.; Alderman, E. L.; Fair, J. M.; Maron, D. J.; Mackey, S. F.; Superko, H. R.; Williams, P. T.; Johnstone, I. M.; Champagne, M. A.; Krauss, R. M.; Farquhar, J. W. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 89:975-990; 1994.
20. Hoffmeister, A.; Rothenbacher, D.; Bazner, U.; Frohlich, M.; Brenner, H.; Hombach, V.; Koenig, W. Role of novel markers of inflammation in patients with stable coronary heart disease. Am. J. Cardiol. 87:262-266; 2001.
21. Hunninghake, D.; Bakker-Arkema, R. G.; Wigand, J. P.; Drehobl, M.; Schrott, H.; Early, J. L.; Abdallah, P.; McBride, S.; Black, D. M. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J. Fam. Pract. 47:349-356; 1998.
22. Ikeda, U. Inflammation and coronary artery disease. Curr. Vasc. Pharmacol. 1:65-70; 2003.
23. Jolliffe, J.; Rees, K.; Taylor, R. S.; Thompson, D.; Oldridge, N. B.; Ebrahim, S. Exercise-based rehabilitation for coronary heart disease. The Cochrane Library, Issue 1. Oxford: 2002:1-25.
24. Jousilahti, P.; Salomaa, V.; Rasi, V.; Vahtera, E.; Palosuo, T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis 156:451-456; 2001.
25. King, D. E.; Carek, P.; Mainous, A. G., III; Pearson, W. S. Inflammatory markers and exercise: differences related to exercise type. Med. Sci. Sports Exerc. 35:575-581; 2003.
26. Koenig, W.; Sund, M.; Frohlich, M.; Fischer, H. G.; Lowel, H.; Doring, A.; Hutchinson, W. L.; Pepys, M. B. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237-242; 1999.
27. König, D.; Berg, A.; Weinstock, C.; Keul, J.; Northoff, H. Essential fatty acids, immune function, and exercise. Exerc. Immunol. Rev. 3:1-31; 1997.
28. Koukkunen, H.; Penttila, K.; Kemppainen, A.; Halinen, M.; Penttila, I.; Rantanen, T.; Pyorala, K. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann. Med. 33:37-47; 2001.
29. Kullo, I. J.; Seward, J. B.; Bailey, K. R.; Bielak, L. F.; Grossardt, B. R.; Sheedy, P. F.; Peyser, P. A.; Turner, S. T. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am. J. Hypertens. 18:1123-1129; 2005.
30. Laberge, M. A.; Moore, K. J.; Freeman, M. W. Atherosclerosis and innate immune signaling. Ann. Med. 37:130-140; 2005.
31. LaMonte, M. J.; Durstine, J. L.; Yanowitz, F. G.; Lim, T.; DuBose, K. D.; Davis, P.; Ainsworth, B. E. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation 106:403-406; 2002.
32. Libby, P.; Ridker, P. M. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 100:1148-1150; 1999.
33. Libby, P.; Theroux, P. Pathophysiology of coronary artery disease. Circulation 111:3481-3488; 2005.
34. Luc, G.; Bard, J. M.; Juhan-Vague, I.; Ferrieres, J.; Evans, A.; Amouyel, P.; Arveiler, D.; Fruchart, J. C.; Ducimetiere, P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler. Thromb. Vasc. Biol. 23:1255-1261; 2003.
35. Luo, Y.; Jiang, D.; Wen, D.; Yang, J.; Li, L. Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin. Heart Vessels 19:257-262; 2004.
36. Marz, W.; Scharnagl, H.; Hoffmann, M. M.; Boehm, B. O.; Winkelmann, B. R. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur. Heart J. 25:2109-2119; 2004.
37. Marz, W.; Winkler, K.; Nauck, M.; Bohm, B. O.; Winkelmann, B. R. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am. J. Cardiol. 92:305-308; 2003.
38. Meredith, I. T.; Plunkett, J. C.; Worthley, S. G.; Hope, S. A.; Cameron, J. D. Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering. Coron. Artery Dis. 16:415-422; 2005.
39. Meurman, J. H.; Janket, S. J.; Qvarnstrom, M.; Nuutinen, P. Dental infections and serum inflammatory markers in patients with and without severe heart disease. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 96:695-700; 2003.
40. Milani, R. V.; Lavie, C. J.; Mehra, M. R. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J. Am. Coll. Cardiol. 43:1056-1061; 2004.
41. Nawawi, H.; Osman, N. S.; Yusoff, K.; Khalid, B. A. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm. Metab Res. 35:479-485; 2003.
42. Pearson, T. A.; Mensah, G. A.; Alexander, R. W.; Anderson, J. L.; Cannon, R. O., III; Criqui, M.; Fadl, Y. Y.; Fortmann, S. P.; Hong, Y.; Myers, G. L.; Rifai, N.; Smith, S. C., Jr.; Taubert, K.; Tracy, R. P.; Vinicor, F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511; 2003.
43. Rattazzi, M.; Puato, M.; Faggin, E.; Bertipaglia, B.; Zambon, A.; Pauletto, P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J. Hypertens. 21:1787-1803; 2003.
44. Ross, R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:115-126; 1999.
45. Rothenbacher, D.; Hoffmeister, A.; Brenner, H.; Koenig, W. Physical activity, coronary heart disease, and inflammatory response. Arch. Intern. Med. 163:1200-1205; 2003.
46. Shepherd, J.; Cobbe, S. M.; Ford, I.; Isles, C. G.; Lorimer, A. R.; Macfarlane, P. W.; McKillop, J. H.; Packard, C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 333:1301-1307; 1995.
47. Stein, E. A. Managing dyslipidemia in the high-risk patient. Am. J Cardiol. 89:50C-57C; 2002.
48. Stroes, E. Statins and LDL-cholesterol lowering: an overview. Curr. Med. Res. Opin. 21 Suppl 6:S9-16; 2005.
49. Tanaka, A.; Shimada, K.; Sano, T.; Namba, M.; Sakamoto, T.; Nishida, Y.; Kawarabayashi, T.; Fukuda, D.; Yoshikawa, J. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J. Am. Coll. Cardiol. 45:1594-1599; 2005.
50. Tsiara, S.; Elisaf, M.; Mikhailidis, D. P. Early vascular benefits of statin therapy. Curr. Med. Res. Opin. 19:540-556; 2003.
51. Verdaet, D.; Dendale, P.; De Bacquer, D.; Delanghe, J.; Block, P.; De Backer, G. Association between leisure time physical activity and markers of chronic inflammation related to coronary heart disease. Atherosclerosis 176:303-310; 2004.
52. Wang, T. D.; Chen, W. J.; Lin, J. W.; Cheng, C. C.; Chen, M. F.; Lee, Y. T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170:315-323; 2003.
53. Willerson, J. T.; Ridker, P. M. Inflammation as a cardiovascular risk factor. Circulation 109:II2-10; 2004.
54. Wood, D.; De Backer, G.; Faergeman, O.; Graham, I.; Mancia, G.; Pyorala, K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140:199-270; 1998.
55. Yudkin, J. S.; Kumari, M.; Humphries, S. E.; Mohamed-Ali, V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209-214; 2000.